Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001628280-19-000571
Filing Date
2019-01-28
Accepted
2019-01-25 20:21:34
Documents
5
Period of Report
2018-11-16
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K -VIBATIV FINANCIAL STATEMENTS a8kaforvibativfs.htm 8-K/A 38579
2 EXHIBIT 23.1 CONSENT OF INDEPENDANT AUDITORS exhibit231.htm EX-23.1 4208
3 EXHIBIT 99.1 2017 VIBATIV SPF exhibit991.htm EX-99.1 91886
4 EXHIBIT 99.2 2018 VIBATIV SPF exhibit992.htm EX-99.2 93867
5 EXHIBIT 99.3 PROFORM exhibit993.htm EX-99.3 231316
  Complete submission text file 0001628280-19-000571.txt   460884
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K/A | Act: 34 | File No.: 001-33637 | Film No.: 19543679
SIC: 2834 Pharmaceutical Preparations